SEPN: Septerna Inc Growth-Adjusted Market Cap to Net Income
Septerna Inc is diversifying its risks by developing therapies for endocrine and immune pathologies through the targeting of cellular receptors. The P/E ratio divided by the growth rate confirms this strategy, where the value of 0.00 characterizes this level. A positive image as a GPCR-sphere innovator is complemented by the leadership's strong scientific foundation and venture capital support following the recent IPO.
Metric breakdowns and analytics for Septerna Inc (SEPN)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
SEPN - Company Net Income|Forward Earnings Septerna Inc|SEPN - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Septerna Pharma|SEPN - PEG Multiple|Company Value to EBITDA Septerna Corp|SEPN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Septerna|SEPN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months septerna.com|SEPN - Earnings growth in current year|Earnings growth forecast for next year Septerna Inc
General company analysis:SEPN - Septerna, Inc.
The PEG ratio compares the market value of earnings to their growth rate, allowing for the identification of undervalued assets when values fall below one. By analyzing the peg_co metric on the GURU.Markets platform, an investor assesses the capitalization potential of Septerna Inc. (SEPN), where the robotization of the Native GPCR platform accelerates drug development, creating a foundation for earnings growth that outpaces the current share price.
Competitors of Septerna Inc
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Pharvaris Pharma PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate tourmalinebio.com (TRML)|Price/Earnings to Growth Ratio Precigen|Pharming Group NV - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple NKTR (Nektar)|Company Value to Earnings Growth Ratio UPB|PEG Multiple ZBIO (Zenas Biopharma Inc)|immunome.com (IMNM) - Price to Earnings Adjusted for Growth Rate|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio KALV (KalVista Pharma)|Pieris Pharmaceuticals Inc (PVLA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio SVRA|RIGL (Rigel Pharmaceuticals) - PEG Multiple|PEG Multiple anaptysbio.com|Price/Earnings to Growth Multiple ATXS (Astria Therapeutics, Inc.)|ENGN (enGene Holdings Inc) - Growth-Adjusted Payback Ratio|PEG Multiple RAPT (RAPT Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Aerovate Therapeutics, Inc. (JBIO)|ACRS - Price/Earnings to Growth Ratio|KYTX (kyvernatx.com) - Growth-Adjusted P/E Ratio|TLSA: PEG Multiple|Price/Earnings to Growth Multiple Cabaletta Bio Inc.|Price/Earnings to Growth Ratio Ventyx Bio|Theratechnologies, Inc (THTX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple AVTX|ELDN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Agenus Inc. AGEN|CLYM (Climb Bio Inc.) - Market Cap to Earnings and Growth Ratio|ZURA - Price/Earnings to Growth Ratio|ATYR (aTyr Pharmaceuticals) - Growth-Adjusted P/E Ratio|adagene.com (ADAG) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - PEG Multiple|EQ: Growth-Adjusted Payback Ratio|PEG Multiple CNTB|PEG Multiple immunic-therapeutics.com (IMUX)|Price/Earnings to Growth Ratio Atara Bio ATRA|Growth-Adjusted Payback Ratio IFRX|XFOR - Price/Earnings to Growth Ratio|Adicet Bio (ACET) - Price/Earnings to Growth Multiple|CELU: PEG Multiple|INmune Bio Corporation (INMB) - PEG Multiple|Price/Earnings to Growth Multiple BRNS|KZR: Growth-Adjusted Payback Ratio|PEG Multiple SABS|Growth-Adjusted Market Cap to Net Income Akari Therapeutics PLC|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Price/Earnings to Growth Multiple|GOVX - Price/Earnings to Growth Ratio|edesabiotech.com (EDSA) - Price/Earnings to Growth Multiple|IBIO (iBio) - Price/Earnings to Growth Multiple|Carisma Therapeutics Inc. (CARM) - PEG Multiple|Price/Earnings to Growth Ratio XTL Biopharmaceuticals, Ltd.|Growth-Adjusted P/E Ratio BOLT (Bolt Bio)|PEG Multiple HCWB|APVO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio AIM ImmunoTech AIM|Growth-Adjusted Market Cap to Net Income Aditxt Inc. (ADTX)|GRI Bio Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate XORTX Corp|Vyome Holdings Inc (HIND) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio REVB (revbiosciences.com)|Price/Earnings to Growth Multiple INDP|SCNI (Scinai Immunotherapeutics Ltd) - Company Value to Earnings Growth Ratio|PEG Multiple CALI|AFMD - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Allakos ALLK|Growth-Adjusted Payback Ratio HOOK|IGMS - Price/Earnings to Growth Ratio|ITOS (iTeos Therapeutics Inc) - Growth-Adjusted P/E Ratio|OCEA: PEG Multiple|TC BioPharm Ltd (TCBP) - PEG Multiple|Price/Earnings to Growth Multiple THRD
